{
    "id": 25471,
    "fullName": "CLDN18 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CLDN18 positive indicates the presence of the CLDN18 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 51208,
        "geneSymbol": "CLDN18",
        "terms": [
            "CLDN18",
            "SFTA5",
            "SFTPJ"
        ]
    },
    "variant": "positive",
    "createDate": "10/10/2016",
    "updateDate": "10/10/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8767,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Claudiximab (IMAB362) to chemotherapy consisted of epirubicin, oxaliplatin, and capecitabine (EOX) resulted in improved progression-free survival (7.9 vs 5.7 months) and overall survival (12.5 vs 8.7 months) compared to EOX alone in patients with advanced gastric and gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl; abstr LBA4001)).",
            "molecularProfile": {
                "id": 26432,
                "profileName": "CLDN18 positive"
            },
            "therapy": {
                "id": 4258,
                "therapyName": "Claudiximab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6736,
                    "pubMedId": null,
                    "title": "FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gast",
                    "url": "http://meetinglibrary.asco.org/content/164788-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8768,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Claudiximab (IMAB362) to chemotherapy consisted of epirubicin, oxaliplatin, and capecitabine (EOX) resulted in improved progression-free survival (7.9 vs 5.7 months) and overall survival (12.5 vs 8.7 months) compared to EOX alone in patients with advanced gastric and gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl; abstr LBA4001)).",
            "molecularProfile": {
                "id": 26432,
                "profileName": "CLDN18 positive"
            },
            "therapy": {
                "id": 4258,
                "therapyName": "Claudiximab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6736,
                    "pubMedId": null,
                    "title": "FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gast",
                    "url": "http://meetinglibrary.asco.org/content/164788-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26432,
            "profileName": "CLDN18 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}